

## Assessment of coronary artery disease during hospitalization for cancer treatment

Simone M. Mrotzek<sup>1</sup>, Alessia Lena<sup>2,3,4,5</sup>, Sara Hadzibegovic<sup>2,3,4,5</sup>, Ria Ludwig<sup>1</sup>, Fadi Al-Rashid<sup>1</sup>, Amir A. Mahabadi<sup>1</sup>, Raluca I. Mincu<sup>1</sup>, Lars Michel<sup>1</sup>, Laura Johannsen<sup>1</sup>, Lena Hinrichs<sup>1</sup>, Martin Schuler<sup>6,7</sup>, Ulrich Keller<sup>8</sup>, Stefan D. Anker<sup>2,4,5</sup>, Ulf Landmesser<sup>3,4,5</sup>, Tienush Rassaf<sup>1</sup>, Markus S. Anker<sup>2,3,4,5</sup>, Matthias Totzeck<sup>1</sup>

<sup>1</sup>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen Hufelandstr. 55, 45147 Essen, Germany

<sup>2</sup>Division of Cardiology and Metabolism, Department of Cardiology, Charité Campus Virchow Klinikum (CVK), Berlin, Germany

<sup>3</sup>Department of Cardiology, Charité Campus Benjamin Franklin (CBF), Berlin, Germany

<sup>4</sup>Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany

<sup>5</sup>DZHK (German Center for Cardiovascular Research), partner site Berlin, Germany

<sup>6</sup>Department of Medical Oncology, West German Cancer Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany

<sup>7</sup>German Cancer Consortium (DKTK), Partner site University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany

<sup>8</sup>Department of Hematology, Oncology and Tumor Immunology, Charité Campus Benjamin Franklin (CBF), Berlin, Germany

### Corresponding author:

Dr. Matthias Totzeck

Department for Cardiology and Vascular Medicine

West German Heart and Vascular Center

Medical Faculty, University Hospital Essen


Hufelandstraße 55, 45147 Essen, Germany

Phone: +49 201 723 4818

Fax: +49 201 723 5401


[Matthias.Totzeck@uk-essen.de](mailto:Matthias.Totzeck@uk-essen.de)

**Supplemental fig. 1**



Rate of performed primary percutaneous coronary intervention (PCI) related to cancer therapy and entity showing no significant differences between groups.

Supplemental fig. 2



Five year all-cause mortality of cancer patients divided in advanced and non-advanced cancer with troponin positive acute coronary syndrome (trop. pos./ STEMI and NSTEMI) or troponin negative angina (trop. neg./ unstable and stable angina). Patients with advanced cancer presented with trop. pos. ACS had the highest mortality, log rank (Mantel Cox) p=0.023.

**Supplemental table 1**

Baseline characteristics of cancer patients with troponin-positive acute coronary syndrome (trop. pos.) vs. troponin-negative angina (trop. neg.)

	<b>Cancer + Trop. neg. (n=77)</b>	<b>Cancer + Trop. pos. (n=76)</b>	<b>P value</b>
<b>Age, years</b>	67.1 (± 11.4)	64.42 (± 11.5)	0.160
<b>Male sex, n (%)</b>	55 (71.4)	57 (75)	0.716
<b>BMI, kg/m<sup>2</sup></b>	26.4 (± 4.8)	25.6 (± 4.8)	0.300
<b>Vascular risk factors, n (%)</b>			
<b>Diabetes mellitus</b>	19 (24.7)	18 (23.7)	1.000
<b>Smoking</b>	30 (39.0)	32 (42.1)	0.743
<b>Hypertension</b>	63 (81.8)	58 (76.3)	0.432
<b>Dyslipidemia</b>	37 (48.1)	37 (48.7)	1.000
<b>Medical history, n (%)</b>			
<b>Coronary artery disease</b>	32 (41.6)	24 (31.6)	0.241
<b>Atrial fibrillation</b>	23 (29.9)	16 (21.1)	0.266
<b>PAOD</b>	8 (10.4)	11 (14.5)	0.473
<b>CAOD</b>	2 (2.6)	6 (7.9)	0.167
<b>Stroke</b>	3 (3.9)	9 (11.8)	0.079
<b>COPD</b>	15 (19.5)	17 (22.4)	0.695
<b>Laboratory findings</b>			
<b>Creatinine, mg/dl</b>	1.03 (0.77-1.32)	1.08 (0.86-1.26)	0.900
<b>GFR &lt;60 ml/min/1.73m<sup>2</sup>, n (%)</b>	33 (42.9)	29 (38.2)	0.622
<b>Hb, g/dl</b>	11.1 (± 1.7)	10.6 (± 1.9)	0.300
<b>Platelet count, /nl</b>	221 (174-282)	215 (152-277)	0.600
<b>Reduced EF (&lt;40%), n (%)</b>	11 (14.7)	16 (23.2)	0.207
<b>Medication history, n (%)</b>			
<b>Acetylsalicylic acid</b>	39 (50.6)	31 (40.8)	0.257
<b>Dual antiplatelet therapy</b>	11 (14.3)	4 (5.3)	0.100
<b>Anticoagulation</b>	8 (10.4)	6 (7.9)	0.780
<b>Statin use</b>	24 (31.2)	20 (26.3)	0.593
<b>Beta-blockers</b>	52 (67.5)	45 (59.2)	0.317

*BMI* body mass index, *PAOD* peripheral artery occlusive disease, *CAOD* cerebral artery occlusive disease, *COPD* chronic obstructive pulmonary disease, *GFR* glomerular filtration rate, *Hb* hemoglobin, *EF* ejection fraction

Data is shown as mean (± SD) or median (IQR)

**Supplemental table 2**

Results of cardiac catheter examinations in Cancer patients with troponin-positive acute coronary syndrome (trop. pos.) vs. troponin-negative angina (trop. neg.)

	<b>Cancer + Trop. neg. (n=77)</b>	<b>Cancer + Trop. pos. (n=76)</b>	<b>P value</b>
<b>Findings, n (%)</b>			
<b>Multivessel disease</b>	37 (48.1)	44 (57.9)	0.258
<b>Absence of CAD</b>	26 (33.8)	18 (23.7)	0.212
<b>CTO</b>	11 (14.3)	18 (23.7)	0.154
<b>LMCA stenosis</b>	7 (9.1)	11 (14.5)	0.327
<b>Culprit lesion</b>	33 (42.9)	41 (53.9)	0.197
<b>Small vessel disease</b>	31 (40.3)	34 (44.7)	0.625
<b>PCI (any)</b>	25 (32.5)	37 (48.7)	0.049*
<b>DES</b>	12 (15.6)	26 (34.2)	0.009*
<b>BMS</b>	11 (14.3)	13 (17.1)	0.663
<b>SYNTAX-score<sup>†</sup></b>			
<b>Baseline-Score</b>	2 (0-7)	7 (0-15.25)	<0.001*
<b>Lowest tertile (<math>\leq 22</math>), n (%)</b>	66 (97.1)	56 (83.6)	0.009*
<b>Intermediate tertile (23-32)</b>	2 (2.9)	7 (10.4)	0.096
<b>Highest tertile (<math>\geq 33</math>)</b>	0	4 (6.0)	0.058
<b>Score post PCI<sup>‡</sup></b>	0 (0)	2 (0-2)	0.170
<b>Residual score &gt;8, n (%)</b>	8 (11.8)	12 (17.9)	0.343
<b>LVEDP<sup>§</sup>, mmHg</b>	13 (5.25-16)	15 (7-22.75)	0.158

*CAD* coronary artery disease, *CTO* chronic total occlusion, *LMCA* left main coronary artery, *PCI* percutaneous coronary intervention, *DES* drug eluting stent, *BMS* bare metal stent, *SYNTAX* SYnergy between PCI with TAXus and cardiac surgery, *LVEDP* left ventricular end-diastolic pressure

Data is shown as median (IQR)

\*Statistically significant difference between Trop. neg. vs. Trop. pos. cancer patients

<sup>†</sup>excluded patients with history for coronary artery bypass surgery, included: Cancer + Trop. neg. n=68, Cancer + Trop pos. n=67

<sup>‡</sup>patients with performed PCI: Cancer + Trop. neg. n=21, Cancer + Trop pos. n=37

<sup>§</sup> documented LVEDP: Cancer + Trop. neg. n=57, Cancer + Trop pos. n=53